A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia
Clinical trial NCT04812925 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04812925
- Sponsor
- argenx
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-17
- Primary completion
- 2026-10-01
- Enrollment
- 173
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.